N-(4'-acetamido)benzoyl-2-methylaniline | 895-98-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4'-acetamido)benzoyl-2-methylaniline
• 英文别名: 4-Acetamino-benz-o-toluidid；4-acetamido-N-(2-methylphenyl)benzamide
• CAS: 895-98-7
• 化学式: C₁₆H₁₆N₂O₂
• mdl: MFCD00578770
• 分子量: 268.315
• InChiKey: JHVQWCURNPWYDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-溴甲苯 、 4-乙酰氨苯甲腈 在 铜 、 potassium carbonate 作用下， 反应 7.0h， 以2%的产率得到N-(4'-cyanophenyl)-2-methylaniline
  参考文献：
  名称：

  Dharmasena, Priyanthi M.; Oliveira-Campos, Ana-M. F.; Raposo, M. Manuela M., Journal of Chemical Research, Miniprint, 1994, # 8, p. 1601 - 1611

  摘要：

  DOI：

文献信息

• NOVEL SOLID FORMS OF TACEDINALINE
  申请人：Holson Edward

  公开号：US20130150450A1

  公开（公告）日：2013-06-13

  Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.

  本发明公开了tacedinaline(4-(乙酰氨基)-N-(2-氨基苯基)苯甲酰胺)的新型固态形式，包括晶体tacedinaline A、B和D，新型晶体tacedinaline TFA盐和非晶态tacedinaline。本发明还公开了含有晶体tacedinaline A、B和D，新型晶体tacedinaline TFA盐和/或非晶态tacedinaline的药物组合物，并公开了通过给予这些新型固态形式治疗各种疾病的方法。
• COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER
  申请人：Fass Daniel

  公开号：US20130039998A1

  公开（公告）日：2013-02-14

  The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.
• US20140275268A1
  申请人：——

  公开号：US20140275268A1

  公开（公告）日：2014-09-18
• US8729130B2
  申请人：——

  公开号：US8729130B2

  公开（公告）日：2014-05-20
• US9266822B2
  申请人：——

  公开号：US9266822B2

  公开（公告）日：2016-02-23